Johnson & Johnson (NYSE:JNJ)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $148.25 and last traded at $148.24, with a volume of 1252521 shares. The stock had previously closed at $147.01.
Several brokerages recently issued reports on JNJ. Cantor Fitzgerald began coverage on shares of Johnson & Johnson in a report on Wednesday, November 27th. They set an “overweight” rating and a $160.00 target price for the company. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $145.00 to $170.00 in a report on Tuesday, December 17th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a report on Wednesday, December 18th. Credit Suisse Group reissued a “buy” rating and set a $163.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 31st. Finally, Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $159.33.
The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. The business’s fifty day simple moving average is $143.07 and its two-hundred day simple moving average is $134.77. The company has a market cap of $385.62 billion, a PE ratio of 18.11, a PEG ratio of 2.36 and a beta of 0.71.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be given a $0.95 dividend. The ex-dividend date is Monday, February 24th. This represents a $3.80 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
In other news, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the sale, the executive vice president now owns 51,736 shares in the company, valued at $7,298,397.52. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. WoodTrust Financial Corp boosted its position in Johnson & Johnson by 4.2% during the third quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock worth $5,995,000 after acquiring an additional 1,848 shares during the last quarter. Park Avenue Securities LLC acquired a new position in Johnson & Johnson during the third quarter worth about $2,939,000. Managed Asset Portfolios LLC boosted its position in Johnson & Johnson by 4.3% during the third quarter. Managed Asset Portfolios LLC now owns 181,153 shares of the company’s stock worth $23,438,000 after acquiring an additional 7,535 shares during the last quarter. Lucia Wealth Services LLC boosted its position in Johnson & Johnson by 2.1% during the third quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock worth $17,072,000 after acquiring an additional 2,744 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Johnson & Johnson by 10.0% during the third quarter. Parallel Advisors LLC now owns 31,912 shares of the company’s stock worth $4,129,000 after purchasing an additional 2,911 shares during the period. Institutional investors and hedge funds own 67.28% of the company’s stock.
About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is a back-end load?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.